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Background: Estrogen deprivation has been shown to increase risks of cardiovascular disease. In obese-insulin resistance, we previously 
shown that cardiac function was markedly compromised, and that metformin (M) and dipeptidyl peptidase-4 inhibitor vildagliptin (Vil) 
improved cardiac function. However, their effects on the heart and cardiac mitochondrial function under estrogen-deprived insulin resistant 
condition are unknown.
methods: Bilateral ovariectomized (O) rats (n= 48) rats were divided to receive either normal diet (NDO) or high-fat diet (HFO) for 12 
weeks, followed by being treated with vehicle, estrogen (E; 50 µg/kg), M (30 mg/kg) or Vil (3 mg/kg) for 4 weeks (n=6/group). Heart rate 
variability (HRV), echocardiography, metabolic and biochemical parameters and cardiac mitochondrial function were determined. Sham-
operated female rats (n= 6) were used as control.
results: Both NDO and HFO rats developed insulin resistance, depressed HRV, decreased %EF, decreased cardiac anti-apoptotic marker 
Bcl-2, and cardiac mitochondrial dysfunction (Figure). Treatments with E, M and Vil improved HRV, Systolic BP and %EF. However, only E 
and Vil, but not M, improved cardiac mitochondrial function in HFO rats.
conclusion:  Although E, Vil and M have similar benefits in improving metabolic status, HRV and cardiac function in estrogen-deprived 
(NDO) rats, only E and Vil, but not M, are effective in preventing cardiac mitochondrial dysfunction in estrogen-deprived insulin resistant 
(HFO) rats.
